GREENWICH LIFESCIENCES, INC. Share-based Payment Arrangement, Expense
GREENWICH LIFESCIENCES, INC. (GLSI) reported Share-based Payment Arrangement, Expense of $4.82 million for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-14.
Discontinued › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2024-08-14
- GREENWICH LIFESCIENCES, INC. share-based payment arrangement, expense for the quarter ending 2024-06-30 was $594.52K, a 0.00% change year-over-year.
- GREENWICH LIFESCIENCES, INC. share-based payment arrangement, expense for the quarter ending 2024-03-31 was $4.22M, a 129.03% increase year-over-year.
- GREENWICH LIFESCIENCES, INC. share-based payment arrangement, expense for the quarter ending 2023-12-31 was $594.52K.
- GREENWICH LIFESCIENCES, INC. share-based payment arrangement, expense for the quarter ending 2023-09-30 was $594.52K.
- GREENWICH LIFESCIENCES, INC. share-based payment arrangement, expense for fiscal 2023 was $3.63M.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $594.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $4.82M 10-Q · filed 2024-08-14 | $5.41M derived: sum of 3 quarters · filed 2024-08-14 | $6.00M derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | $4.22M 10-Q · filed 2024-05-20 | $4.82M derived: sum of 2 quarters · filed 2024-05-20 | $5.41M derived: sum of 3 quarters · filed 2024-05-20 | $6.00M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-12-31 | $594.52K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $1.19M derived: sum of 2 quarters · filed 2024-04-15 | $1.78M derived: sum of 3 quarters · filed 2024-08-14 | $3.63M 10-K · filed 2024-04-15 |
| 2023-09-30 | $594.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-19 | $1.19M derived: sum of 2 quarters · filed 2024-08-14 | $3.03M 10-Q · filed 2023-10-19 | |
| 2023-06-30 | $594.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $2.44M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $1.84M 10-Q · filed 2024-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |